Literature DB >> 8774190

Improvement of severe pulmonary hypertension in a patient with SLE.

M Karmochkine, B Wechsler, P Godeau, F Brenot, J L Jagot, G Simonneau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8774190      PMCID： PMC1010242          DOI： 10.1136/ard.55.8.561

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus.

Authors:  P Goupille; L Fauchier; D Babuty; J P Fauchier; J P Valat
Journal:  J Rheumatol       Date:  1994-10       Impact factor: 4.666

2.  Pulmonary hypertension in a lupus clinic: experience with twenty-four patients.

Authors:  R A Asherson; T W Higenbottam; A T Dinh Xuan; M A Khamashta; G R Hughes
Journal:  J Rheumatol       Date:  1990-10       Impact factor: 4.666

3.  Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus.

Authors:  T M Winslow; M A Ossipov; G P Fazio; J S Simonson; R F Redberg; N B Schiller
Journal:  Am Heart J       Date:  1995-03       Impact factor: 4.749

4.  Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide.

Authors:  H Groen; H Bootsma; D S Postma; C G Kallenberg
Journal:  J Rheumatol       Date:  1993-06       Impact factor: 4.666

5.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

6.  Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy.

Authors:  M Dahl; A Chalmers; J Wade; D Calverley; B Munt
Journal:  J Rheumatol       Date:  1992-11       Impact factor: 4.666
  6 in total
  5 in total

Review 1.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats.

Authors:  Stefan Bogdan; Andrei Seferian; Andreea Totoescu; Stefan Dumitrache-Rujinski; Mihai Ceausu; Cristin Coman; Carmen-Maria Ardelean; Maria Dorobantu; Miron Bogdan
Journal:  Maedica (Buchar)       Date:  2012-06

3.  Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide.

Authors:  Eri Sugawara; Masaru Kato; Ryo Hisada; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

Review 4.  DNA Damage and Pulmonary Hypertension.

Authors:  Benoît Ranchoux; Jolyane Meloche; Roxane Paulin; Olivier Boucherat; Steeve Provencher; Sébastien Bonnet
Journal:  Int J Mol Sci       Date:  2016-06-22       Impact factor: 5.923

5.  Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway.

Authors:  Lei Gao; Jun Liu; Yongmei Hao; Zengren Zhao; Huilian Tan; Jie Zhang; Ning Meng; Qinghou Zheng; Zhen Wang; Yi Zhang
Journal:  Iran J Basic Med Sci       Date:  2018-03       Impact factor: 2.699
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.